Sun Pharma’s Q1FY25 Results

• Sun Pharma reported a 5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended June (Q1FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9%.
• Its expenses for the quarter were up by 1% QoQ and 5% YoY.
• The net profit grew 7% QoQ and 40% YoY.
• The earnings per share (EPS) of Sun Pharma stood at 11.8 during Q1FY25.

Sun Pharma’s Financial Statements for Q1FY25:

Financials:

• Revenue: Revenue increased by 9% YoY to ₹13,185 crores, up from ₹12,145 crores in Q1FY24.
• Net Profit: 40% YoY increase to ₹2,836 crores, from ₹2,023 crores in Q1FY24.
• EBITDA: 8.3% YoY increase to ₹3,607 crores from ₹3,331.7 crores.
• EBITDA Margin: Improved by 60 basis points to 28.5% from 27.9% in the same period last year.
• Earnings per Share: The EPS for Q1FY25 stood at ₹11.8, compared to ₹8.4 in Q1FY24.
• Indian Market Performance: Formulation sales in India increased by 16.4% to ₹4,144 crores (33.1% of total sales).
• R&D Expenses: Increased to ₹794 crores, up from ₹680 crores in Q1FY24.

Management Commentary:

Dilip Shanghvi, Chairman and Managing Director of Sun Pharmaceutical Industries, said,

“Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe and the completion of the acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings and will help us serve patients better.”

Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.